2016
Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies
Samad Z, Velazquez EJ. Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies. Current Cardiology Reports 2016, 18: 128. PMID: 27796864, DOI: 10.1007/s11886-016-0808-8.Peer-Reviewed Original Research
2015
Current and emerging modalities for detection of cardiotoxicity in cardio-oncology
Khouri MG, Klein MR, Velazquez EJ, Jones LW. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. Future Cardiology 2015, 11: 471-484. PMID: 26235924, PMCID: PMC5558528, DOI: 10.2217/fca.15.16.Peer-Reviewed Original ResearchConceptsEarly detectionLife-saving cancer therapyCurative-intent therapyCancer-specific mortalityCancer-specific survivalCardiovascular risk factorsDetection of cardiotoxicityFunctional capacity testingNovel adjuvant therapyDegree of cardiotoxicityAdjuvant therapyCardiovascular morbidityCardiovascular mortalityCardiovascular dysfunctionCardiovascular injuryBlood biomarkersRisk factorsEarly preventionCancer treatmentCardiotoxicityTherapyMortalityCancer therapyDiagnostic toolInjury
2014
Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure)
Stewart RA, Szalewska D, She L, Lee KL, Drazner MH, Lubiszewska B, Kosevic D, Ruengsakulrach P, Nicolau JC, Coutu B, Choudhary SK, Mark DB, Cleland JG, Piña IL, Velazquez EJ, Rynkiewicz A, White H. Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure). JACC Heart Failure 2014, 2: 335-343. PMID: 25023813, PMCID: PMC4127151, DOI: 10.1016/j.jchf.2014.02.009.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryIschemic left ventricular dysfunctionLeft ventricular dysfunctionArtery bypass graft surgeryBypass graft surgeryPoor exercise capacityExercise capacityMedical therapyVentricular dysfunctionSTICH trialGraft surgeryBetter exercise capacityWalk testMedical managementPrognostic significanceTreatment allocationPhysical activityPatientsEarly riskHigh mortalityMortalityTherapyDysfunctionSurgeryTrials
2012
Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome
Bart B, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal Of Medicine 2012, 367: 2296-2304. PMID: 23131078, PMCID: PMC3690472, DOI: 10.1056/nejmoa1210357.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureSerum creatinine levelsHeart failureUltrafiltration groupRenal functionCreatinine levelsPharmacologic therapyAdverse eventsEnd pointSafety of ultrafiltrationPrimary end pointSerious adverse eventsTreatment of patientsPersistent congestionDiuretic therapyCardiorenal syndromeRandomized trialsMean changePatientsBody weightWeight lossTherapySignificant differencesHigh rate
2011
No Mortality Benefit from CABG When Added to Optimal Medical Therapy in Patients with CAD and LV Dysfunction: Results from the STICH Trial
Velazquez E. No Mortality Benefit from CABG When Added to Optimal Medical Therapy in Patients with CAD and LV Dysfunction: Results from the STICH Trial. MD Conference Express 2011, 11: 20-21. DOI: 10.1177/155989771103012.Peer-Reviewed Original ResearchCoronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1607-1616. PMID: 21463150, PMCID: PMC3415273, DOI: 10.1056/nejmoa1100356.Peer-Reviewed Original ResearchConceptsMedical therapy groupCardiovascular causesCoronary artery diseaseMedical therapyCABG groupRate of deathArtery diseasePrimary outcomeMajor secondary outcomesCoronary artery bypassPrimary end pointArtery bypass surgeryLeft ventricular dysfunctionTreatment of patientsVentricular dysfunctionBypass surgerySecondary outcomesEjection fractionHeart failureCABGPatientsTherapyEnd pointHospitalizationDeathMyocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA. Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1617-1625. PMID: 21463153, PMCID: PMC3290901, DOI: 10.1056/nejmoa1100358.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular DiseasesCombined Modality TherapyCoronary Artery BypassCoronary Artery DiseaseEchocardiography, StressFemaleFollow-Up StudiesHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial IschemiaMyocardiumProportional Hazards ModelsStatistics, NonparametricTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftConceptsCoronary artery diseaseVentricular dysfunctionMedical therapyMyocardial viabilityArtery diseaseViable myocardiumSurvival benefitBaseline variablesIschemic left ventricular dysfunctionDifferential survival benefitSubstudy of patientsCoronary artery bypassLeft ventricular dysfunctionDobutamine echocardiographyUnderwent assessmentPatientsCABGDysfunctionTreatment assignmentTherapyMyocardiumDiseaseGreater likelihoodMortalityTrials
2007
Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy
Tang Z, Diamond MA, Chen J, Holly TA, Bonow RO, Dasgupta A, Hyslop T, Purzycki A, Wagner J, McNamara DM, Kukulski T, Wos S, Velazquez EJ, Ardlie K, Feldman AM. Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy. Clinical Pharmacology & Therapeutics 2007, 82: 435-440. PMID: 17728764, DOI: 10.1038/sj.clpt.6100331.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsBase SequenceCardiomyopathiesCase-Control StudiesDNA Mutational AnalysisGene FrequencyGenetic Predisposition to DiseaseHeart VentriclesHumansMolecular Sequence DataMutationMyocardial InfarctionMyocardial IschemiaPhenotypePolymorphism, Single NucleotideReceptor, Adenosine A1Receptor, Adenosine A2AReceptor, Adenosine A3Risk FactorsSeverity of Illness IndexVentricular Function, LeftConceptsIschemic cardiomyopathyInfarct sizeAdenosine receptor geneReceptor geneGenetic variantsPopulation of patientsVentricular functionVentricular sizeIschemic preconditioningNormal controlsHeart responseAdenosine receptorsCardiomyopathyIschemiaPatientsIndividual responsesDNA samplesResponsePolymorphismTherapyInjuryGenesVariantsExceptional early blood pressure control rates: The ACCOMPLISH trial
Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M, Jamerson K, Bakris G, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen S, Cushman W, Papademetriou V, Weber M. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Pressure 2007, 16: 80-86. PMID: 17612905, DOI: 10.1080/08037050701395571.Peer-Reviewed Original ResearchConceptsBP control ratesControl rateCombination therapyHigh-risk hypertensionMean BP changeMulti-national trialStage 2 hypertensionAnti-hypertensive medicationsBlood pressure controlACCOMPLISH trialMaximal medicationHypertension trialsMean BPRenal diseaseInitial treatmentBP changesHypotensive eventsCurrent guidelinesPressure controlHypertensionOverall trialPatientsTherapyTrialsAnalysis of variance
2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trialThe first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension
JAMERSON K, BAKRIS G, WUN C, DAHLOF B, LEFKOWITZ M, MANFREDA S, PITT B, VELAZQUEZ E, WEBER M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trialThe first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. American Journal Of Hypertension 2004, 17: 793-801. DOI: 10.1016/s0895-7061(04)00840-4.Peer-Reviewed Original Research